<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03802123</url>
  </required_header>
  <id_info>
    <org_study_id>IAB-CD8-201</org_study_id>
    <nct_id>NCT03802123</nct_id>
  </id_info>
  <brief_title>⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors</brief_title>
  <acronym>iCorrelate</acronym>
  <official_title>A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImaginAb, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImaginAb, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to&#xD;
      establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by&#xD;
      immunohistochemical staining in patients with selected advanced and metastatic solid&#xD;
      malignancies who are scheduled to receive standard of care immunotherapy. The study will also&#xD;
      evaluate uptake of ⁸⁹Zr-Df-IAB22M2C by PET/CT in patients at baseline and on immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will be evaluated to determine eligibility for study entry. Up to 1 week&#xD;
      prior to initiation of immunotherapy, patients will receive an injection of ⁸⁹Zr-Df-IAB22M2C&#xD;
      (1.0 mCi) and will undergo PET/CT scanning to determine baseline uptake of ⁸⁹Zr-Df-IAB22M2C&#xD;
      in tumor lesions and reference tissues. Patients will receive an additional injection of&#xD;
      ⁸⁹Zr-Df-IAB22M2C (1.0 mCi) and PET/CT scan 4-6 weeks after starting immunotherapy&#xD;
      (on-therapy) to evaluate uptake of ⁸⁹Zr-Df-IAB22M2C in tumor lesions and reference tissues,&#xD;
      and to assess potential changes in uptake of ⁸⁹Zr-Df-IAB22M2C compared to the baseline scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Actual">July 18, 2022</completion_date>
  <primary_completion_date type="Actual">October 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of ⁸⁹Zr-Df-IAB22M2C uptake in biopsied tumors with CD8+ cell measurement by immunohistochemistry (IHC)</measure>
    <time_frame>Baseline to 4-5 weeks after the start of immunotherapy</time_frame>
    <description>Analyze ⁸⁹Zr-Df-IAB22M2C uptake in biopsied tumors as determined by SUV-based quantitative measures (SUVmax, SUVpeak, SUVmean, CD8 tumor volume, and tumor:reference tissue ratio) with CD8+ cell measurement determined by IHC from biopsy samples.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Time of infusion of ⁸⁹Zr-Df-IAB22M2C (Visit 2 Day 1) through 4-5 weeks after the second infusion of ⁸⁹Zr-Df-IAB22M2C</time_frame>
    <description>The incident and severity of adverse events per CTCAE criteria will be recorded following repeat doses of ⁸⁹Zr-Df-IAB22M2C. ria, changes in laboratory test results, vital signs, and 12- lead electrocardiogram findings prior to and within 1 hour post injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Signs and symptoms of infusion reactions</measure>
    <time_frame>Time of infusion of ⁸⁹Zr-Df-IAB22M2C (Visit 2 Day 1) through 4-5 weeks after the second infusion of ⁸⁹Zr-Df-IAB22M2C</time_frame>
    <description>Signs and symptoms of infusion reactions following repeat doses of ⁸⁹Zr-Df-IAB22M2C will be assessed evaluating the incidence and severity of local and systemic signs and symptoms of infusion reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in WBC differential including percentages of total WBC and absolute counts: (neutrophils, immature neutrophils, lymphocytes, monocytes, eosinophils, basophils) laboratory values compared to baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>WBC differential including percentages of total WBC and absolute counts: (neutrophils, immature neutrophils, lymphocytes, monocytes, eosinophils, basophils) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in mean corpscular volume (fL) laboratory values compared to baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>mean corpscular volume (fL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in hematocrit (%) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>hematocrit (%) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in hemoglobin (g/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>hemoglobin (g/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in platelet count (thousands/ul) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>platelet count (thousands/ul) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in WBC count (thousands/ul) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>WBC count (thousands/ul) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in RBC count (millions/uL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>RBC count (millions/uL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood glucose (mg/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>blood glucose (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in chloride (mmol/L) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>chloride (mmol/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in potassium (mmol/L) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Potassium (mmol/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in sodium (mmol/L) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>sodium (mmol/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in uric acid (mg/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>uric acid (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in serum creatinine (mg/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>serum creatinine (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in GGT (U/L) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>GGT (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in BUN (mg/dL) laboratory values compared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>BUN (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in LDH (U/L) laboratory values comapared with baseline</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>LDH (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bilirubin, direct and total (mg/dL) laboratory values</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Change/shifts in Bilirubin, direct and total (mg/dL) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALP laboratory values</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Change/shifts in ALP (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALT laboratory values</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Change/shifts in ALT (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AST laboratory values</measure>
    <time_frame>prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion</time_frame>
    <description>Change/shifts in AST (U/L) laboratory values compared with baseline results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-Lead electrocardiogram</measure>
    <time_frame>Within 60 minutes post-infusion (study visits 2 and 5)</time_frame>
    <description>Proportion of subjects with abnormal electrocardiogram findings prior to and within 1 hour post injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of blood pressure</measure>
    <time_frame>15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)</time_frame>
    <description>Changes/shifts in blood pressure (systolic and diastolic)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of heart rate</measure>
    <time_frame>15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)</time_frame>
    <description>Changes/shifts in heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of respiration rate</measure>
    <time_frame>15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)</time_frame>
    <description>Changes/shifts in respiration rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of temperature</measure>
    <time_frame>15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)</time_frame>
    <description>Changes/shifts in temperature</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Baseline and On-treatment ⁸⁹Zr-Df-IAB22M2C uptake and distribution in tumors and lymphoid organs, and measurement of change between the paired observations</measure>
    <time_frame>5 weeks</time_frame>
    <description>Assessment of Baseline and On-treatment ⁸⁹Zr-Df-IAB22M2C uptake and distribution in tumors and lymphoid organs, and measurement of change between the paired observations as determined by:&#xD;
Tumor uptake analysis as described by visual scoring scales&#xD;
Lymph node chain visibility defined as location and number of nodes in lymph node chains identified with elevated ⁸⁹Zr-Df-IAB22M2C activity.&#xD;
SUV-based quantitative analysis (e.g. SUVmax, SUVpeak, SUVmean, CD8 tumor volume (volume of tumor tissues with increased CD8 uptake with SUV &gt;40% SUVmax), and Tumor:Reference ratios&#xD;
Visual and SUV-based quantitative analysis (e.g. SUVmax, SUVpeak, SUVmean) in tumor and reference tissue including lymph nodes, spleen, and bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of change in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in biopsied tumors as determined by SUV-based quantitative analysis</measure>
    <time_frame>7 weeks</time_frame>
    <description>Measurement of change in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in biopsied tumors as determined by SUV-based quantitative analysis (e.g. SUVmax, SUVpeak, SUVmean, CD8 tumor volume (volume of tumor tissues with increase CD8 uptake with SUV &gt; 40% SUVmax) and Tumor: Reference ratio from Baseline to On- Treatment PET scans and correlation with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of biodistribution patterns of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) on PETbaseline and PETTx and any changes in biodistribution between baseline and On-Treatment.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Description of biodistribution patterns of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) on PETbaseline and PETTx and any changes in biodistribution between baseline and On-Treatment. PETbaseline and PETTx scans compared to change in CD8+ T cells in tumor lesions by IHC if the same lesion was biopsied at Baseline and On-Treatment visits</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of the variance in gene expression profiles in subjects prior to and On-treatment as measured in whole blood by Nanostring analysis.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Evaluation of the variance in gene expression profiles in subjects prior to and On-treatment as measured in whole blood by Nanostring analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of visual and quantitative ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in tumor lesions with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Correlation of visual and quantitative ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in tumor lesions with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Estimation of positive predictive value, negative predictive value, sensitivity and specificity of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) PET for detecting CD8+ T cells as determined by IHC.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Estimation of positive predictive value, negative predictive value, sensitivity and specificity of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) PET for detecting CD8+ T cells as determined by IHC.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of changes in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake and distribution from baseline to 5-7 days start of immunotherapy if available.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Assessment of changes in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake and distribution from baseline to 5-7 days start of immunotherapy if available.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with clinical outcomes (response rates, duration of response, disease stability rate and PFS at defined intervals as determined by the local investigator.</measure>
    <time_frame>18 months</time_frame>
    <description>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with clinical outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with radiologic responses</measure>
    <time_frame>7 weeks</time_frame>
    <description>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with radiologic responses based upon:&#xD;
Correlation of subject response by RECIST 1.1 compared to visual and quantitative SUVbased analysis&#xD;
Correlation of RECIST target lesion response as determined by best change in lesion diameter while on immunotherapy compared to visual and quantitative SUV based analysis at baseline and On-treatment PET/CT scans.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) tumor and lymph node uptake with immune infiltrates and other molecular biomarker (CD8) expression by IHC</measure>
    <time_frame>7 weeks</time_frame>
    <description>Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) tumor and lymph node uptake with immune infiltrates and other molecular biomarker (CD8) expression by IHC</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of the 89Zr-Df-IAB22M2C(CD8 PET Tracer) uptake on a subset of PETbaseline and PETtx scans that have been virtually reconstructed with lower theoretical doses of 8⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) with CD8+ T cells from IHC analysis.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Correlation of the 89Zr-Df-IAB22M2C(CD8 PET Tracer) uptake on a subset of PETbaseline and PETtx scans that have been virtually reconstructed with lower theoretical doses of 8⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) with CD8+ T cells from IHC analysis.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Positron-Emission Tomography</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>⁸⁹Zr-Df-IAB22M2C Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>⁸⁹Zr-Df-IAB22M2C</intervention_name>
    <description>⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)</description>
    <arm_group_label>⁸⁹Zr-Df-IAB22M2C Infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants will be eligible for enrollment in the study only if they meet ALL of the&#xD;
        following criteria:&#xD;
&#xD;
          1. 1. Patients with advanced or metastatic Melanoma, Non-Small Cell Lung Cancer, Renal&#xD;
             Cell Carcinoma or Squamous Cell Carcinoma of the Head and Neck with at least one&#xD;
             non-radiated lesion, who are scheduled to begin standard of care immunotherapy.&#xD;
&#xD;
          2. • At least 1 non radiated measurable lesion documented on CT/, MRI (per RECIST&#xD;
             criteria 1.1) or are FDG avid on FDG-PET within 45 days prior to first&#xD;
             89Zr-Df-IAB22M2C (CD8 PET Tracer) infusion.&#xD;
&#xD;
          3. At least 1 non-cutaneous lesion that is accessible, per investigator's assessment, and&#xD;
             eligible for biopsy. If only a single RECIST measurable lesion is present,&#xD;
             investigator to determine if the tumor biopsy could interfere with RECIST assessments&#xD;
             of response.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
          5. Meeting all clinical safety lab values per institution's standard of care, or&#xD;
             Investigator's discretion, for patients receiving cancer treatment.&#xD;
&#xD;
          6. Age ≥ 18 years.&#xD;
&#xD;
          7. Ability to understand the purposes and risks of the trial and has signed an&#xD;
             IRB-approved informed consent form.&#xD;
&#xD;
          8. Willingness and ability to comply with all protocol required procedures.&#xD;
&#xD;
          9. For men and women of child-producing potential, use of effective double barrier&#xD;
             contraceptive methods during the study, up to 30 days after the last administration of&#xD;
             the investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will NOT be eligible for enrollment in the study if they meet ANY of the following&#xD;
        criteria:&#xD;
&#xD;
          1. Serious nonmalignant disease or conditions that in the opinion of the investigator&#xD;
             and/or ImaginAb could compromise protocol objectives.&#xD;
&#xD;
          2. Patients with a single RECIST measurable lesion, biopsy of which, per investigator's&#xD;
             assessment, is likely to interfere with RECIST assessments of response.&#xD;
&#xD;
          3. Patients who have any splenic disorders, or had splenectomy, that in the opinion of&#xD;
             the investigator and/or ImaginAb could compromise protocol objectives.&#xD;
&#xD;
          4. Pregnant women or nursing mothers.&#xD;
&#xD;
          5. 5. Life expectancy &lt; 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Korn, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ImaginAb, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama-Birmingham Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARTI Cancer Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope (City of Hope National Medical Center, City of Hope Medical Center)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAC + USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute at Providence Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/ University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>November 15, 2022</last_update_submitted>
  <last_update_submitted_qc>November 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>⁸⁹Zr-Df-IAB22M2C</keyword>
  <keyword>CD8</keyword>
  <keyword>Imaging</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03802123
org study id: IAB-CD8-201
nct id: NCT03802123
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to
      establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by
      immunohistochemical staining in patients with selected advanced and metastatic solid
      malignancies who are scheduled to receive standard of care immunotherapy. The study will also
      evaluate uptake of ⁸⁹Zr-Df-IAB22M2C by PET/CT in patients at baseline and on immunotherapy.
After being informed about the study and potential risks, all patients giving written
      informed consent will be evaluated to determine eligibility for study entry. Up to 1 week
      prior to initiation of immunotherapy, patients will receive an injection of ⁸⁹Zr-Df-IAB22M2C
      (1.0 mCi) and will undergo PET/CT scanning to determine baseline uptake of ⁸⁹Zr-Df-IAB22M2C
      in tumor lesions and reference tissues. Patients will receive an additional injection of
      ⁸⁹Zr-Df-IAB22M2C (1.0 mCi) and PET/CT scan 4-6 weeks after starting immunotherapy
      (on-therapy) to evaluate uptake of ⁸⁹Zr-Df-IAB22M2C in tumor lesions and reference tissues,
      and to assess potential changes in uptake of ⁸⁹Zr-Df-IAB22M2C compared to the baseline scan.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Diagnostic
masking: None (Open Label)
measure: Correlation of ⁸⁹Zr-Df-IAB22M2C uptake in biopsied tumors with CD8+ cell measurement by immunohistochemistry (IHC)
time frame: Baseline to 4-5 weeks after the start of immunotherapy
description: Analyze ⁸⁹Zr-Df-IAB22M2C uptake in biopsied tumors as determined by SUV-based quantitative measures (SUVmax, SUVpeak, SUVmean, CD8 tumor volume, and tumor:reference tissue ratio) with CD8+ cell measurement determined by IHC from biopsy samples.
measure: Adverse events
time frame: Time of infusion of ⁸⁹Zr-Df-IAB22M2C (Visit 2 Day 1) through 4-5 weeks after the second infusion of ⁸⁹Zr-Df-IAB22M2C
description: The incident and severity of adverse events per CTCAE criteria will be recorded following repeat doses of ⁸⁹Zr-Df-IAB22M2C. ria, changes in laboratory test results, vital signs, and 12- lead electrocardiogram findings prior to and within 1 hour post injection.
measure: Signs and symptoms of infusion reactions
time frame: Time of infusion of ⁸⁹Zr-Df-IAB22M2C (Visit 2 Day 1) through 4-5 weeks after the second infusion of ⁸⁹Zr-Df-IAB22M2C
description: Signs and symptoms of infusion reactions following repeat doses of ⁸⁹Zr-Df-IAB22M2C will be assessed evaluating the incidence and severity of local and systemic signs and symptoms of infusion reactions
measure: Change in WBC differential including percentages of total WBC and absolute counts: (neutrophils, immature neutrophils, lymphocytes, monocytes, eosinophils, basophils) laboratory values compared to baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: WBC differential including percentages of total WBC and absolute counts: (neutrophils, immature neutrophils, lymphocytes, monocytes, eosinophils, basophils) laboratory values compared with baseline results.
measure: Changes in mean corpscular volume (fL) laboratory values compared to baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: mean corpscular volume (fL) laboratory values compared with baseline results.
measure: Changes in hematocrit (%) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: hematocrit (%) laboratory values compared with baseline results.
measure: Changes in hemoglobin (g/dL) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: hemoglobin (g/dL) laboratory values compared with baseline results.
measure: Changes in platelet count (thousands/ul) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: platelet count (thousands/ul) laboratory values compared with baseline results.
measure: Changes in WBC count (thousands/ul) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: WBC count (thousands/ul) laboratory values compared with baseline results.
measure: Changes in RBC count (millions/uL) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: RBC count (millions/uL) laboratory values compared with baseline results.
measure: Changes in blood glucose (mg/dL) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: blood glucose (mg/dL) laboratory values compared with baseline results.
measure: Changes in chloride (mmol/L) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: chloride (mmol/L) laboratory values compared with baseline results.
measure: Changes in potassium (mmol/L) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: Potassium (mmol/L) laboratory values compared with baseline results.
measure: Changes in sodium (mmol/L) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: sodium (mmol/L) laboratory values compared with baseline results.
measure: Changes in uric acid (mg/dL) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: uric acid (mg/dL) laboratory values compared with baseline results.
measure: Changes in serum creatinine (mg/dL) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: serum creatinine (mg/dL) laboratory values compared with baseline results.
measure: Changes in GGT (U/L) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: GGT (U/L) laboratory values compared with baseline results.
measure: Changes in BUN (mg/dL) laboratory values compared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: BUN (mg/dL) laboratory values compared with baseline results.
measure: Changes in LDH (U/L) laboratory values comapared with baseline
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: LDH (U/L) laboratory values compared with baseline results.
measure: Bilirubin, direct and total (mg/dL) laboratory values
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: Change/shifts in Bilirubin, direct and total (mg/dL) laboratory values compared with baseline results.
measure: ALP laboratory values
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: Change/shifts in ALP (U/L) laboratory values compared with baseline results.
measure: ALT laboratory values
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: Change/shifts in ALT (U/L) laboratory values compared with baseline results.
measure: AST laboratory values
time frame: prior to infusion ⁸⁹Zr-Df-IAB22M2C on study Day 1 and at 4-7 weeks; and 24 +/- 3 hrs after infusions (study Day 2 and 4-7 weeks); and at 4-6 weeks after 2nd infusion
description: Change/shifts in AST (U/L) laboratory values compared with baseline results.
measure: 12-Lead electrocardiogram
time frame: Within 60 minutes post-infusion (study visits 2 and 5)
description: Proportion of subjects with abnormal electrocardiogram findings prior to and within 1 hour post injection.
measure: Evaluation of blood pressure
time frame: 15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)
description: Changes/shifts in blood pressure (systolic and diastolic)
measure: Evaluation of heart rate
time frame: 15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)
description: Changes/shifts in heart rate
measure: Evaluation of respiration rate
time frame: 15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)
description: Changes/shifts in respiration rate
measure: Evaluation of temperature
time frame: 15 +/- 5 minutes prior to infusion and within 60 minutes post-infusion (study visits 2 and 5) and 4-6 weeks after 2nd infusion (study visit 8)
description: Changes/shifts in temperature
measure: Assessment of Baseline and On-treatment ⁸⁹Zr-Df-IAB22M2C uptake and distribution in tumors and lymphoid organs, and measurement of change between the paired observations
time frame: 5 weeks
description: Assessment of Baseline and On-treatment ⁸⁹Zr-Df-IAB22M2C uptake and distribution in tumors and lymphoid organs, and measurement of change between the paired observations as determined by:
Tumor uptake analysis as described by visual scoring scales
Lymph node chain visibility defined as location and number of nodes in lymph node chains identified with elevated ⁸⁹Zr-Df-IAB22M2C activity.
SUV-based quantitative analysis (e.g. SUVmax, SUVpeak, SUVmean, CD8 tumor volume (volume of tumor tissues with increased CD8 uptake with SUV >40% SUVmax), and Tumor:Reference ratios
Visual and SUV-based quantitative analysis (e.g. SUVmax, SUVpeak, SUVmean) in tumor and reference tissue including lymph nodes, spleen, and bone marrow.
measure: Measurement of change in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in biopsied tumors as determined by SUV-based quantitative analysis
time frame: 7 weeks
description: Measurement of change in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in biopsied tumors as determined by SUV-based quantitative analysis (e.g. SUVmax, SUVpeak, SUVmean, CD8 tumor volume (volume of tumor tissues with increase CD8 uptake with SUV > 40% SUVmax) and Tumor: Reference ratio from Baseline to On- Treatment PET scans and correlation with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.
measure: Description of biodistribution patterns of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) on PETbaseline and PETTx and any changes in biodistribution between baseline and On-Treatment.
time frame: 7 weeks
description: Description of biodistribution patterns of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) on PETbaseline and PETTx and any changes in biodistribution between baseline and On-Treatment. PETbaseline and PETTx scans compared to change in CD8+ T cells in tumor lesions by IHC if the same lesion was biopsied at Baseline and On-Treatment visits
measure: Evaluation of the variance in gene expression profiles in subjects prior to and On-treatment as measured in whole blood by Nanostring analysis.
time frame: 7 weeks
description: Evaluation of the variance in gene expression profiles in subjects prior to and On-treatment as measured in whole blood by Nanostring analysis.
measure: Correlation of visual and quantitative ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in tumor lesions with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.
time frame: 7 weeks
description: Correlation of visual and quantitative ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in tumor lesions with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.
measure: Estimation of positive predictive value, negative predictive value, sensitivity and specificity of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) PET for detecting CD8+ T cells as determined by IHC.
time frame: 7 weeks
description: Estimation of positive predictive value, negative predictive value, sensitivity and specificity of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) PET for detecting CD8+ T cells as determined by IHC.
measure: Assessment of changes in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake and distribution from baseline to 5-7 days start of immunotherapy if available.
time frame: 7 weeks
description: Assessment of changes in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake and distribution from baseline to 5-7 days start of immunotherapy if available.
measure: Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with clinical outcomes (response rates, duration of response, disease stability rate and PFS at defined intervals as determined by the local investigator.
time frame: 18 months
description: Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with clinical outcomes
measure: Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with radiologic responses
time frame: 7 weeks
description: Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake with radiologic responses based upon:
Correlation of subject response by RECIST 1.1 compared to visual and quantitative SUVbased analysis
Correlation of RECIST target lesion response as determined by best change in lesion diameter while on immunotherapy compared to visual and quantitative SUV based analysis at baseline and On-treatment PET/CT scans.
measure: Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) tumor and lymph node uptake with immune infiltrates and other molecular biomarker (CD8) expression by IHC
time frame: 7 weeks
description: Correlation of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) tumor and lymph node uptake with immune infiltrates and other molecular biomarker (CD8) expression by IHC
measure: Correlation of the 89Zr-Df-IAB22M2C(CD8 PET Tracer) uptake on a subset of PETbaseline and PETtx scans that have been virtually reconstructed with lower theoretical doses of 8⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) with CD8+ T cells from IHC analysis.
time frame: 7 weeks
description: Correlation of the 89Zr-Df-IAB22M2C(CD8 PET Tracer) uptake on a subset of PETbaseline and PETtx scans that have been virtually reconstructed with lower theoretical doses of 8⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) with CD8+ T cells from IHC analysis.
arm group label: ⁸⁹Zr-Df-IAB22M2C Infusion
arm group type: Experimental
description: A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.
intervention type: Drug
intervention name: ⁸⁹Zr-Df-IAB22M2C
description: ⁸⁹Zr-Df-IAB22M2C CD8 T cell tracer for Positron Emission Tomography (PET)
arm group label: ⁸⁹Zr-Df-IAB22M2C Infusion
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Ron Korn, MD, PhD
role: Study Director
affiliation: ImaginAb, Inc.
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United States
responsible party type: Sponsor
sharing ipd: No